Christopher Raymond
Stock Analyst at Piper Sandler
(2.51)
# 2,271
Out of 4,893 analysts
135
Total ratings
50.46%
Success rate
-1.19%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $134.70 | -14.63% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.50 | +1,690.33% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $58.90 | +113.92% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $2.32 | +72.41% | 3 | Feb 11, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $7 → $8 | $4.60 | +73.91% | 8 | Jan 27, 2025 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $109 → $119 | $129.34 | -7.99% | 4 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $480.71 | +10.88% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $561.44 | +80.43% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $29.95 | +367.45% | 5 | Jan 13, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Overweight | $72 | $41.12 | +75.10% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $196.27 | +12.09% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.57 | +728.03% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $4.98 | +1,406.02% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $14.83 | +412.47% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $1.43 | +599.30% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $10.07 | +227.71% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.55 | +174.51% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $8.37 | +401.79% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $11.08 | +98.56% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $3.98 | +0.63% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $8.61 | +190.53% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $299.81 | -3.94% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $39.10 | +4.86% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $53.81 | -47.97% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $80.93 | -50.57% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.34 | +1,585.39% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.41 | +6,708.51% | 2 | Mar 13, 2020 |
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $134.70
Upside: -14.63%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.50
Upside: +1,690.33%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $58.90
Upside: +113.92%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $2.32
Upside: +72.41%
Ardelyx
Jan 27, 2025
Maintains: Neutral
Price Target: $7 → $8
Current: $4.60
Upside: +73.91%
Blueprint Medicines
Jan 27, 2025
Maintains: Neutral
Price Target: $109 → $119
Current: $129.34
Upside: -7.99%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $480.71
Upside: +10.88%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $561.44
Upside: +80.43%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $29.95
Upside: +367.45%
Monopar Therapeutics
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $41.12
Upside: +75.10%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $196.27
Upside: +12.09%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.57
Upside: +728.03%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $4.98
Upside: +1,406.02%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $14.83
Upside: +412.47%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $1.43
Upside: +599.30%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $10.07
Upside: +227.71%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.55
Upside: +174.51%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $8.37
Upside: +401.79%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $11.08
Upside: +98.56%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $3.98
Upside: +0.63%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $8.61
Upside: +190.53%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $299.81
Upside: -3.94%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $39.10
Upside: +4.86%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $53.81
Upside: -47.97%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $80.93
Upside: -50.57%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.34
Upside: +1,585.39%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.41
Upside: +6,708.51%